Abstract: In thymidine analogue mutations, K70R mutation was the most common (37.2%), followed by D67N, T215F and T69N mutations (27.9%, 27.9% and 25.6%, respectively).
Discussion: TAMs occur in different patterns: type 1 includes M41L, L210W and T215Y (14%, 11.6% and 4.7% prevalence, respectively, in our study), and type 2 includes K70R, D67N T215F and K219Q/E (37.2%, 27.9%, 27.9% and 14% prevalence, respectively, in our study).
Discussion: The accumulation of other mutations observed included TAMs (including M41L, L210W,
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Table: D67N
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Result: M184V/I (236/372, 63.44%), K65KR/R (78/372, 20.97%), D67DN/N (77/372, 20.70%), and K70E/R/KR (72/372, 19.35%) were most common NRTI-related mutations.
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
PMID: 31660328
2019
Open forum infectious diseases
Method: Information on thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E) before the switch to ABC/3TC/DTG also was obtained.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 31660328
2019
Open forum infectious diseases
Result: Among the 21 patients who experienced VF, 2 had 3 archived TAMs (D67N, K70R, and K219Q/E and M41L, K70R, and K219Q/E), including the M184V/I mutation.
Result: One patient had 2 TAMs (D67N and K219Q/E) without an archived M184V/I mutation.
The Frequency of HIV-1 Infection in Iranian Children and Determination of the Transmitted Drug Resistance in Treatment-Naive Children.
Abstract: The phylogenetic analyses of the amplified region of pol gene indicated that all of the 15 HIV-1-infected pediatric patients were infected by CRF35_AD, and a total of 13.3% (2/15) of these children were infected with HIV-1 variants with SDRMs (one child harbored two related SDRMs [D67N, V179F], and another child had three related SDRMs [M184V, T215F, and K103N]), according to the last algorithm of the WHO.
Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
Result: Eleven (25%, 11/44) of the RTRM were thymidine analogue mutations (T215FY [2.5%, 6/239], K70R [1.7%, 4/239] and 0.8% (2/239) each of D67N, L210W, M41L, and K219Q/E (Fig 2).
Result: The mutational pattern, D67N-M41L-M184V-L210W-T215F/Y was the most resistant conferring HLR to all drugs in the class, except tenofovir that showed intermediate resistance (IR) (Table 2).
Table: D67N
The association between detected drug resistance mutations and CD4(+) T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
Abstract: Among individuals with at least one DRM, we found evidence that any nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, the reverse transcriptase (RT) mutations M184V, D67N and T215Y as well as the protease mutations V82A and I54V were associated with reduced CD4 declines.
HIV mutation literature information.
PMID: 
2019
Infection and drug resistance
Browser Board
Co-occurred Entities
Filtrator
ViMRT